Literature DB >> 35699874

Role of Ubiquitin-Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance.

Subhashree Sahoo1, Amrita Arpita Padhy1, Varsha Kumari1, Parul Mishra2.   

Abstract

Synuclein aggregation in neuronal cells is the primary underlying cause of synucleinopathies. Changes in gene expression patterns, structural modifications, and altered interactions with other cellular proteins often trigger aggregation of α-synuclein, which accumulates as oligomers or fibrils in Lewy bodies. Although fibrillar forms of α-synuclein are primarily considered pathological, recent studies have revealed that even the intermediate states of aggregates are neurotoxic, complicating the development of therapeutic interventions. Autophagy and ubiquitin-proteasome pathways play a significant role in maintaining the soluble levels of α-synuclein inside cells; however, the heterogeneous nature of the aggregates presents a significant bottleneck to its degradation by these cellular pathways. With studies focused on identifying the proteins that modulate synuclein aggregation and clearance, detailed mechanistic insights are emerging about the individual and synergistic effects of these degradation pathways in regulating soluble α-synuclein levels. In this article, we discuss the impact of α-synuclein aggregation on autophagy-lysosome and ubiquitin-proteasome pathways and the therapeutic strategies that target various aspects of synuclein aggregation or degradation via these pathways. Additionally, we also highlight the natural and synthetic compounds that have shown promise in alleviating the cellular damage caused due to synuclein aggregation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aggregate clearance; Autophagy; Chaperone-mediated autophagy; Neurodegenerative diseases; Oligomers; Parkinson’s disease; Proteasome; Small molecules; Synucleinopathies; Ubiquitin; α-Synuclein

Mesh:

Substances:

Year:  2022        PMID: 35699874     DOI: 10.1007/s12035-022-02897-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  98 in total

1.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

Authors:  J E Galvin; K Uryu; V M Lee; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 2.  Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.

Authors:  Emily M Rocha; Briana De Miranda; Laurie H Sanders
Journal:  Neurobiol Dis       Date:  2017-04-08       Impact factor: 5.996

Review 3.  Occupational metal exposures and the risk of Parkinson's disease.

Authors:  J M Gorell; B A Rybicki; C Cole Johnson; E L Peterson
Journal:  Neuroepidemiology       Date:  1999       Impact factor: 3.282

Review 4.  Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease.

Authors:  Songzhe He; Shan Zhong; Gang Liu; Jun Yang
Journal:  Neurodegener Dis       Date:  2021-01-19       Impact factor: 2.977

5.  Incidence of dementia with Lewy bodies and Parkinson disease dementia.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; Bradley F Boeve; J Eric Ahlskog; Walter A Rocca
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

6.  Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.

Authors:  Martí Colom-Cadena; Ellen Gelpi; Sara Charif; Olivia Belbin; Rafael Blesa; Maria J Martí; Jordi Clarimón; Alberto Lleó
Journal:  J Neuropathol Exp Neurol       Date:  2013-12       Impact factor: 3.685

7.  Rotenone, paraquat, and Parkinson's disease.

Authors:  Caroline M Tanner; Freya Kamel; G Webster Ross; Jane A Hoppin; Samuel M Goldman; Monica Korell; Connie Marras; Grace S Bhudhikanok; Meike Kasten; Anabel R Chade; Kathleen Comyns; Marie Barber Richards; Cheryl Meng; Benjamin Priestley; Hubert H Fernandez; Franca Cambi; David M Umbach; Aaron Blair; Dale P Sandler; J William Langston
Journal:  Environ Health Perspect       Date:  2011-01-26       Impact factor: 9.031

Review 8.  The Emerging Evidence of the Parkinson Pandemic.

Authors:  E Ray Dorsey; Todd Sherer; Michael S Okun; Bastiaan R Bloem
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

9.  α-Synuclein promotes dilation of the exocytotic fusion pore.

Authors:  Todd Logan; Jacob Bendor; Chantal Toupin; Kurt Thorn; Robert H Edwards
Journal:  Nat Neurosci       Date:  2017-03-13       Impact factor: 24.884

10.  Pathological Endogenous α-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy.

Authors:  Seiji Kaji; Takakuni Maki; Hisanori Kinoshita; Norihito Uemura; Takashi Ayaki; Yasuhiro Kawamoto; Takahiro Furuta; Makoto Urushitani; Masato Hasegawa; Yusuke Kinoshita; Yuichi Ono; Xiaobo Mao; Tran H Quach; Kazuhiro Iwai; Valina L Dawson; Ted M Dawson; Ryosuke Takahashi
Journal:  Stem Cell Reports       Date:  2018-01-11       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.